Literature DB >> 15110453

Dosimetric effect of respiratory motion in external beam radiotherapy of the lung.

James Mechalakos1, Ellen Yorke, Gikas S Mageras, Agung Hertanto, Andrew Jackson, Ceferino Obcemea, Kenneth Rosenzweig, C Clifton Ling.   

Abstract

BACKGROUND AND
PURPOSE: To study the effect of breathing motion on gross tumor volume (GTV) coverage for lung tumors using dose-volume histograms and relevant dosimetric indices. PATIENTS AND METHODS: Treatment plans were chosen for 12 patients treated at our institution for lung carcinoma. GTV volumes of these patients ranged from 1.2 to 97.3 cm(3). A margin of 1-2 cm was used to generate the planning target volume (PTV). Additional margins of 0.6-1.0 cm were added to the PTV when designing treatment portals. For the purposes of TCP calculation, the prescription dose was assumed to be 70 Gy to remove the effects of prescription differences. Setup error was incorporated into the evaluation of treatment plans with a systematic component of sigma(RL) = 0.2 cm, sigma(AP) = 0.2 cm, and sigma(SI) = 0.3 cm and a random component of sigma(RL) = 0.3 cm, sigma(AP) = 0.3 cm, and sigma(SI) = 0.3 cm. Breathing motion was incorporated into these plans based on an independent analysis of fluoroscopic movies of the diaphragm for 7 patients. The systematic component of breathing motion (sigma(RL) = 0.3 cm, sigma(AP) = 0.2 cm, and sigma(SI) = 0.6 cm) was incorporated into the treatment plans on a slice by slice basis. The intrafractional component of breathing motion (sigma(RL) = 0.3 cm, sigma(AP) = 0.2 cm, and sigma(SI) = 0.6 cm) was incorporated by averaging the dose calculation over all displacements of the breathing cycle. Each patient was simulated 500 times to discern the range of possible outcomes. The simulations were repeated for a worst case scenario which used only breathing data with a large diaphragmatic excursion, both with and without intrafractional breathing motion.
RESULTS: Dose to 95% of the GTV (D95), volume of the GTV receiving 95% of the prescription dose (V95) and TCP changed an average of -1.4+/-4.2, -1.0+/-3.3, and -1.4+/-3.8%, respectively, with the incorporation of normal breathing effects. In the worst case scenario (heavy breathers), D95 and V95 changed an average of -9.8+/-10.1 and -8.3+/-11.3%, respectively, and TCP changed by -8.1+/-9.1%. GTVs with volumes greater than 60 cm(3) showed stronger sensitivity to breathing especially if the shape was non-ellipsoidal. In the normal breathing case, the probability of a decrease in D95, V95, or TCP of a magnitude greater than 10% is less than 4%, and in the worse case scenario this probability is approximately 30-40% with intrafractional breathing motion included, and less than 10% with intrafractional breathing motion not included.
CONCLUSIONS: With the PTV margins routinely used at our center, the effects of normal breathing on coverage are small on the average, with a less than 4% chance of a 10% or greater decrease in D95, V95, or TCP. However, in patients with large respiration-induced motion, the effect can be significant and efforts to identify such patients are important.

Entities:  

Mesh:

Year:  2004        PMID: 15110453     DOI: 10.1016/j.radonc.2004.01.011

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Evaluating the image quality of cone beam CT acquired during rotational delivery.

Authors:  S A Yoganathan; K J Maria Das; K Maria Midunvaleja; D Gowtham Raj; Arpita Agarwal; J Velmurugan; Shaleen Kumar
Journal:  Br J Radiol       Date:  2015-07-30       Impact factor: 3.039

2.  Automatically gated image-guided breath-hold IMRT is a fast, precise, and dosimetrically robust treatment for lung cancer patients.

Authors:  Anna Simeonova-Chergou; Anika Jahnke; Kerstin Siebenlist; Florian Stieler; Sabine Mai; Judit Boda-Heggemann; Frederik Wenz; Frank Lohr; Lennart Jahnke
Journal:  Strahlenther Onkol       Date:  2016-01-15       Impact factor: 3.621

3.  The correlation of tissue motion within the lung: implications on fiducial based treatments.

Authors:  Ryan L Smith; Deshan Yang; Andrew Lee; Martin L Mayse; Dan A Low; Parag J Parikh
Journal:  Med Phys       Date:  2011-11       Impact factor: 4.071

4.  Adaptive radiation for lung cancer.

Authors:  Daniel R Gomez; Joe Y Chang
Journal:  J Oncol       Date:  2010-08-04       Impact factor: 4.375

5.  Observation of interfractional variations in lung tumor position using respiratory gated and ungated megavoltage cone-beam computed tomography.

Authors:  Jenghwa Chang; Gig S Mageras; Ellen Yorke; Fernando De Arruda; Jussi Sillanpaa; Kenneth E Rosenzweig; Agung Hertanto; Hai Pham; Edward Seppi; Alex Pevsner; C Clifton Ling; Howard Amols
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-01       Impact factor: 7.038

6.  Setup error analysis in helical tomotherapy based image-guided radiation therapy treatments.

Authors:  Bhagyalakshmi Akkavil Thondykandy; Jamema V Swamidas; Jayprakash Agarwal; Tejpal Gupta; Sarbani G Laskar; Umesh Mahantshetty; Shrinivasan S Iyer; Indrani U Mukherjee; Shyam K Shrivastava; Deepak D Deshpande
Journal:  J Med Phys       Date:  2015 Oct-Dec

7.  Interfractional anatomic variation in patients treated with respiration-gated radiotherapy.

Authors:  Ellen Yorke; Kenneth E Rosenzweig; Raquel Wagman; Gikas S Mageras
Journal:  J Appl Clin Med Phys       Date:  2005-05-19       Impact factor: 2.102

8.  Performance evaluation of respiratory motion-synchronized dynamic IMRT delivery.

Authors:  S A Yoganathan; K J Maria Das; Arpita Agarwal; Shaleen Kumar
Journal:  J Appl Clin Med Phys       Date:  2013-05-06       Impact factor: 2.102

9.  Tumor control probability reduction in gated radiotherapy of non-small cell lung cancers: a feasibility study.

Authors:  R Alfredo Siochi; Yusung Kim; Sudershan Bhatia
Journal:  J Appl Clin Med Phys       Date:  2014-10-16       Impact factor: 2.102

10.  Dosimetric characteristics of a new linear accelerator under gated operation.

Authors:  Sergey Kriminski; Alex N Li; Timothy D Solberg
Journal:  J Appl Clin Med Phys       Date:  2006-02-15       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.